Table 2.
Examining visit- and lab-defined retention in care thresholds in SLE cases with and without nephritis (n = 397)
| All SLE | Lupus nephritis | p | ||||
|---|---|---|---|---|---|---|
| n = 397 | n = 145 | |||||
| Definition | Interval | n | % | n | % | |
| Visit definitions | ||||||
| Rh visits | ≥ 1/year | 331 | 83 | 120 | 83 | 0.802 |
| *Rh visits | ≥ 2/year | 238 | 60 | 96 | 66 | 0.054 |
| Rh visits | ≥ 4/year | 79 | 20 | 46 | 32 | < 0.001 |
| Lab definitions | ||||||
| C3/C4 | ≥ 1/year | 184 | 46 | 78 | 54 | 0.024 |
| *C3/C4 | ≥ 2/year | 106 | 27 | 49 | 34 | 0.015 |
| C3/C4 | ≥ 4/year | 30 | 8 | 20 | 14 | < 0.001 |
| CBC | ≥ 1/year | 213 | 54 | 90 | 62 | 0.011 |
| CBC | ≥ 2/year | 159 | 40 | 72 | 50 | 0.001 |
| CBC | ≥ 4/year | 93 | 23 | 52 | 36 | 0.003 |
| Creatinine | ≥ 1/year | 211 | 53 | 89 | 61 | 0.013 |
| Creatinine | ≥ 2/year | 163 | 41 | 74 | 51 | 0.002 |
| Creatinine | ≥ 4/year | 92 | 23 | 49 | 34 | < 0.001 |
| dsDNA | ≥ 1/year | 149 | 38 | 67 | 46 | 0.007 |
| dsDNA | ≥ 2/year | 77 | 19 | 39 | 27 | 0.004 |
| dsDNA | ≥ 4/year | 18 | 5 | 12 | 8 | 0.007 |
Abbreviations: Rh rheumatology MD, DO, NP, PA, or fellow; C3/C4 complement component 3 or 4 lab tests which were each independently assessed yielding identical results that are shown together; CBC complete blood counts; dsDNA double-stranded DNA antibody test
*Final models used two visits and at least two labs per year consistent with WHO/CDC HIV definitions and ACR SLE guidelines